Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning.
about
T Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical OutcomeGuidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveImproving cytomegalovirus-specific T cell reconstitution after haploidentical stem cell transplantationProtective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimenAspergillus infections in transplant recipients.Interleukin-21 promotes thymopoiesis recovery following hematopoietic stem cell transplantation.Long-term immune deficiency after allogeneic stem cell transplantation: B-cell deficiency is associated with late infections.Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation.Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients.Thymic T-cell development in allogeneic stem cell transplantationA comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignanciesValganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trialAssociation of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipientsMonocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation.Immune restoration following hematopoietic stem cell transplantation: an evolving target.Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantationHow I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantationAllogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioningTiming and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation.Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.Natural and adoptive T-cell immunity against herpes family viruses after allogeneic hematopoietic stem cell transplantation.Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation.Sirolimus enhances the effect of apoptotic cell infusion on hematopoietic engraftment and tolerance inductionFludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention.Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT.Infectious complications following allogeneic stem cell transplantation: reduced-intensity vs. myeloablative conditioning regimens.Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen.Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %-a feasibility study.Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation.Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants.Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodomiJoint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34-Selected to CD3/CD19-Depleted Grafts in a Retrospective Multicenter Study
P2860
Q28072227-242E694F-808B-4192-91B9-19BB12624D47Q28388806-A7EA85A3-9C24-4BB3-B644-6359AAB3C430Q33597783-A5FFD323-0658-44E8-A389-86C13C642A2DQ33645271-B6C2BE0B-1D3B-4AEA-B1C6-DE6F4557AB86Q33719294-85BACA6A-DFAA-4F57-B85B-426944C756C2Q33802076-AC37D846-1B57-477A-8ABD-61C2A29F04CDQ33886257-3AB5901E-802E-4AFC-A5E8-BB9BBF61C1A4Q34798117-F91BC65A-C8B7-4D25-966D-6AFC78C7A62FQ35018548-3F51CC92-B2E7-4C82-ADEC-8BD10B0F9AA4Q35083246-F7BBB5EB-E977-4AF9-B170-CF67DA05CDF7Q35285087-718BA57A-8390-46E9-989C-54473F1F464FQ35554703-3801010E-5751-4DEE-8E64-DC3954652BA9Q35735525-38FA8D05-9186-4255-A2A8-CDAC6C487DFBQ35811940-8435128D-A269-4A45-81D9-13F158490AADQ35847753-604AF945-D134-42ED-B1C3-C92566D4A9E9Q36075296-81655960-B9A6-4593-B1D5-EFF834AD1B2AQ36959201-2B248304-DE69-4F55-BEAC-2FB0EAB1335FQ36965855-DAFEC027-D361-43AA-A1D9-6ECBBEDA98D1Q37220343-CF71E1A8-4869-458F-B977-8540290BDC45Q37284406-C02C98DA-3D6D-4FA3-8EC0-4B9799305761Q37390571-9F6C6FC1-4DCE-4FD6-9466-5F56319A459DQ37888687-6E2DBECC-05B9-412D-8290-5C1EA75B6148Q42214333-34EF9EBA-46E6-4720-9814-BFF42ABCA4FBQ42280856-17FDB49F-CC33-42AC-9E3B-A23CEE76B5C9Q43241788-0A534B9C-113A-4CE3-BA98-2D090DF6BB44Q44951826-918E4B46-B7D5-4D97-9393-C8E1C4D6BEB0Q45143156-B5B00495-9872-4BD1-99F3-D30B12F0F8C5Q45327796-7DA514E5-E33A-408C-973E-317F207B5E95Q46896203-5F32B2CD-BD39-4D39-99F3-55CB38C9CB32Q53116636-001FB3B8-6BCF-4BC9-BB2B-D8D20C9687E0Q53597155-D04CF891-47E4-4E0B-BAAF-F38EEBF52CE8Q53636461-9A13EEA0-3C34-44CC-8148-18DCD0DE9574Q53649676-B3C2C567-07D2-4421-B9D1-A027D17D3DA0Q58781733-56C041B7-E511-4F12-80A9-E704F9AF282F
P2860
Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Immunologic recovery after hem ...... nonmyeloablative conditioning.
@en
Immunologic recovery after hem ...... nonmyeloablative conditioning.
@nl
type
label
Immunologic recovery after hem ...... nonmyeloablative conditioning.
@en
Immunologic recovery after hem ...... nonmyeloablative conditioning.
@nl
prefLabel
Immunologic recovery after hem ...... nonmyeloablative conditioning.
@en
Immunologic recovery after hem ...... nonmyeloablative conditioning.
@nl
P2093
P50
P1476
Immunologic recovery after hem ...... nonmyeloablative conditioning.
@en
P2093
Jan Storek
Kristen White
Michael Keng
Michael Maris
Monja Dawson
P304
P356
10.1016/S0301-472X(03)00201-7
P577
2003-10-01T00:00:00Z